Stryker Corp. Q4 Profit Rises Amid Strong Orthopedic and Neurotech Sales

Stryker Corp. (SYK) reported higher fourth-quarter profit on January 29, 2026, driven by robust demand for orthopedic implants and neurotechnology products, signaling sustained recovery in elective procedures. Net income rose 12% year-over-year to $842 million, or $2.21 per diluted share, beating analyst estimates of $2.14. Revenue climbed 7.3% to $5.82 billion, fueled by 8.1% growth in its MedSurg and Neurotech segment. CEO Kevin Lobo cited “broad-based strength across geographies” and improved hospital staffing as key catalysts. The company reaffirmed its 2026 organic sales growth guidance of 6%–7.5%, with operating margin expansion expected despite inflationary pressures. Shares rose 2.4% in after-hours trading.